Recent News

• 05.06.2026 - Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
• 04.14.2026 - Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
• 04.07.2026 - Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
• 03.30.2026 - Anavex Life Sciences Provides Comprehensive Regulatory Update
• 03.25.2026 - Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
• 03.23.2026 - Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
• 03.20.2026 - New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
• 03.20.2026 - New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
• 02.25.2026 - Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
• 02.25.2026 - Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

Recent Filings

• 05.01.2026 - 3 Initial statement of beneficial ownership of securities
• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.25.2026 - EX-99.1 EX-99.1
• 03.25.2026 - 8-K Current report
• 02.25.2026 - EX-99.1 EX-99.1
• 02.25.2026 - 8-K Current report
• 02.09.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.09.2026 - 8-K Current report
• 02.09.2026 - EX-99.1 EX-99.1